HCW Biologics shares skyrocketed as the company entered a licensing agreement with China's WY Biotech for an immunotherapeutic product candidate.

China's stock market is likely headed for tougher times ahead, at least according to a few prominent Wall Street firms.

The FTSE 100 and European markets opened higher on Monday, heading higher from a dip last week where investors took profits ...

Ford has more than a century of history and innovation behind it, but now BYD, a young Chinese automaker, is barreling around ...

The Chinese e-commerce leader is issuing bonds denominated in US-dollar and yuan to help repay debt and fund stock ...

Futu Holdings (NASDAQ:FUTU) is scheduled to announce Q3 earnings results on Tuesday, November 19th, before market open. The ...

Tesla stock is up 37% in volatile post-election trading as Wall Street digests a complicated web of Trump policies which may ...

The streamlined regulatory system would greatly benefit Tesla founder Elon Musk, who became a close Trump ally during his ...

At least five cargoes of liquefied natural gas have diverted from Asia to Europe in the past few days, drawn by higher gas prices on the continent after Russia's Gazprom halted supplies to Austria's ...

Nvidia's stock has surged more than 2,600% in the past five years according to Yahoo Finance data, fueled by one impressive ...

When we investigated some of the claims cited in the posts, we found that some were accurate, some were wrong and most of the rest omitted context ...

(Bloomberg) -- Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a ...